Roche ad­justs Avastin fran­chise de­fense plans as PhII suc­ces­sor fails a key study

Vanu­cizum­ab was sup­posed to be Roche’s an­swer to the biosim­i­lars of Avastin that are now steadi­ly wind­ing their way through the clin­ic on a short path to reg­u­la­tors. But in a Phase II head-to-head be­tween new and old, the suc­ces­sor drug failed to dis­tin­guish it­self. And now Roche is drop­ping its de­vel­op­ment as a monother­a­py while push­ing on with com­bos and high hopes for its mar­quee check­point drug Tecen­triq.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.